Level C· Early human research exploring benefitsProspective StudyPubMed

Changes in body composition in children with acute graft-versus-host disease within the first 100 days after hematopoietic stem cell transplantation.

Feng Y., Pan LY., Shen LY., Chang PP., Zhang BH., Hong L.

Prospective Study on Immune Modulation, published in Eur J Clin Nutr (2017) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Eur J Clin Nutr (2017)
Country
England
Reported sample size
—
Source database
PubMed
PMID
29269889
DOI
10.1038/s41430-017-0057-y

Abstract (original English)

Acute graft-versus-host-disease (aGVHD) is one of the main complications of hematopoietic stem cell transplantation (HSCT). This study investigated the changes in body composition of pediatric patients with aGVHD during the first 100 days after HSCT. Fifty-five children receiving HSCT were divided into two groups (aGVHD and non-aGVHD). Body mass index Z-scores (BMI-z), arm muscle area index (AMAI), fat mass index (FMI), and fat-free mass index (FFMI) were measured on the day of transplantation (H0), and on the 30th (H30), 60th (H60), and 100th day (H100) after the transplantation. The correlative factors on body composition were evaluated. In the aGVHD group, the rates of absolute change of BMI-z at H30, H60, and H100 showed a significant increase as compared to that at H0, especially at H30 which was remarkably higher than that of the non-aGVHD group (P = 0.008). AMAI showed a continuous decrease from H0 to H100 in the aGVHD group; also FFMI was found to be lower than that of the non-aGVHD group during the first 100 days after transplantation, however, no significant differences were found between the two groups. At H60 and H100, FFMI in the aGVHD group was lower than that in the non-aGVHD group (P = 0.014, P = 0.032, respectively). Glucocorticoid treatment and the occurrence of mucositis were the key factors for changes in body composition in the aGVHD group. Changes in body

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Acute DiseaseAdipose TissueAdolescentAnthropometryBody CompositionBody Mass IndexChildChild, PreschoolFemaleGraft vs Host Disease

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research